Grosse Pointe Farms

Researchers are evaluating multi-cancer detection (MCD) tests as new tools to screen for multiple cancers at once by measuring markers in the blood. This trial aims to explore how well these tests work for cancer screening, their impact on patients and doctors in making care decisions, and how to conduct such studies in the future. Adults aged 45 to 75 without cancer are included to help assess the feasibility and performance of these MCD tests compared to standard care. Participants are randomly assigned to one of three groups: two groups undergo blood collection for different MCD tests called Shield and Avantect at enrollment and after one year, and a control group undergoes blood collection without MCD testing. Some study sites provide participants with their test results (unblinded) while others only provide abnormal results (blinded). Those with abnormal results are advised to follow up with their clinicians for further testing. After the intervention, participants are followed passively for up to 10 years. Throughout the study, participants complete questionnaires and provide blood samples at specified times. Researchers collect medical record data and monitor adherence to the protocol, timing of test result returns, diagnostic follow-ups for abnormal results, and participants' anxiety and cancer worry. The study measures feasibility outcomes such as enrollment, follow-up completion, and diagnostic resolution, as well as clinical performance of the MCD tests. Safety and long-term outcomes, including cancer incidence and mortality, are also observed.